Advances in Novel Biologics Targeting BAFF/APRIL in the Treatment of IgA Nephropathy
Cells · 26.01.2026 · 15 (3) · 240
DOI: 10.3390/cells15030240 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 26.01.2026. Verfasst von Yiduo Xu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Chinese Medicine, State Key Laboratory of Mechanism and Quality of Chinese Medicine, Medical Sciences Division, Macau University of Scienc…. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Tumor Necrosis Factor Ligand Superfamily Member 13, B-Cell Activating Factor, Biological Products. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Development Fund of Macau.
Abstract (Originalsprache)
IgA nephropathy (IgAN) is the most common primary chronic glomerular disease worldwide. Its clinical features include proteinuria and complement pathway activation, which are the strongest predictors of progression to renal failure. This disease can occur at any age. Approximately 30–40% of IgAN patients progress to end-stage renal disease (ESRD) within 20–25 years after diagnosis, making it one of the major causes of ESRD. As understanding of the autoimmune development of IgA nephropathy (IgAN) grows, research shows that BAFF and APRIL promote B-cell activation by binding to the receptors TACI, BCMA, and BAFF-R. This results in the overproduction of galactose-deficient IgA1 (Gd-IgA1), which helps drive the progression of IgA nephropathy. B-cell and plasma cell-targeted therapies, such as biologics against BAFF/APRIL, can precisely and effectively improve patient symptoms. Corresponding agents have now been successfully developed and are administered via subcutaneous or intravenous injection. Clinical trials have demonstrated the significant effectiveness of this approach, especially in reducing proteinuria, stabilizing eGFR, and lowering Gd-IgA1 levels. Although current trial data for BAFF/APRIL-targeted biologics in IgA nephropathy are promising, these new treatments need ongoing clinical monitoring for long-term infection risks and potential drug resistance. This article focuses on the application of BAFF/APRIL biologics in the treatment of IgA nephropathy, addressing gaps in existing literature. While prior studies have emphasized the mechanisms of action of these drugs in IgA nephropathy, they have lacked a comprehensive summary of the current status of specific drug research and clinical progress.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Chinese Medicine, State Key Laboratory of Mechanism and Quality of Chinese Medicine, Medical Sciences Division, Macau University of Science and Technology, Taipa, Macao, China.
- Macau University of Science and Technology Zhuhai MUST Science and Technology Research Institute, Hengqin, Zhuhai 519031, China.
ORCID-Profile: Yiduo Xu
Förderung
- Science and Technology Development Fund of Macau
Zitieren
APA
Xu, Y., Mo, Y., & Xu, Y. (2026). Advances in Novel Biologics Targeting BAFF/APRIL in the Treatment of IgA Nephropathy. Cells, 15(3), 240. https://doi.org/10.3390/cells15030240
Vancouver
Xu Y, Mo Y, Xu Y. Advances in Novel Biologics Targeting BAFF/APRIL in the Treatment of IgA Nephropathy. Cells. 2026;15(3):240. doi:10.3390/cells15030240
BibTeX
@article{Xu2026,
author = {Xu, Yiduo and Mo, Yingqiu and Xu, Youhua},
title = {Advances in Novel Biologics Targeting BAFF/APRIL in the Treatment of IgA Nephropathy},
journal = {Cells},
year = {2026},
volume = {15},
number = {3},
pages = {240},
doi = {10.3390/cells15030240}
}
EUVIMED